Fly News Breaks for February 21, 2020
Feb 21, 2020 | 07:07 EDT
H.C. Wainwright analyst Douglas Tsao lowered the firm's price target on TherapeuticsMD to $6 from $7 and reiterates a Buy rating on the shares. While the company's Q4 report was better than the preannouncement, the numbers below the headline "don't quite live up to expectations," Tsao tells investors in a research note. Despite the "noise around Q," the analyst thinks the company's portfolio remains positioned for growth, especially Annovera based on product differentiation and strong reimbursement.
News For TXMD From the Last 2 Days
There are no results for your query TXMD